We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
Date | Subject | Author | Discuss |
---|---|---|---|
28/12/2022 20:00 | Hopefully 2023 will be a good year for gak sp | alibizzle | |
25/12/2022 09:49 | Let's just use this thread? | tradermichael | |
24/12/2022 16:41 | GlaxoSmithKline – defensive attractions The pharmaceutical sector tends to offer defensive attractions as doctors and patients are always in need of the companies’ products, regardless of the machinations of the worldwide economy. Shares in GlaxoSmithKline recently got a shot in the arm after a US judge threw out 2,500 major lawsuits that claimed its heartburn drug Zantac caused cancer. Analysts at broker Morgan Stanley had been concerned that the issue could have cost the company $45 billion in compensation claims. While there is still the possibility of individual lawsuits against Glaxo, this ruling ends a substantial concern for investors and a major overhang on the shares. | bountyhunter | |
24/12/2022 16:15 | Q3 dividend pays out on 12 January 2023. Not long now ;o) | tradermichael | |
24/12/2022 12:52 | I have every confidence in GSK’s future prospects and turnaround strategy buy buy buy! | paul planet earth | |
24/12/2022 01:16 | Merry Xmas cya Wednesday | letsdothis | |
23/12/2022 21:44 | GSK is a Shares Mag tip for 2023 | bountyhunter | |
23/12/2022 13:22 | Another twonk appears.. wonder if there is a limit to my filter list? ;) | rikky72 | |
23/12/2022 12:07 | Wishing you all a merry Xmas From the shorts & the BOILER ROOM exposing team enjoy your holidays & remember family is the most important thing EVER money is EASY to replace family can't be replaced WITH NO AMOUNT OF MONEY | letsdothis | |
23/12/2022 11:50 | I would advise to be MEGA CARFUL | letsdothis | |
23/12/2022 11:50 | BANKRUPTCY could loom | letsdothis | |
23/12/2022 11:50 | I think that many law claims being made will GSK be able to survive after 6 months ? | letsdothis | |
23/12/2022 11:49 | Being SUED LEFT RIGHT & centre | letsdothis | |
23/12/2022 11:49 | Hence they have got some many liable claims being made | letsdothis | |
23/12/2022 11:34 | Troll alert | alibizzle | |
23/12/2022 11:28 | STOP LYING NO TAKE OVER PEOPLE THESE ARE BOILER ROOM SCUM IGNORE THEM IL EXPLAIN IF YOU GOOGLE A "stock boiler room" you will see what these people do Now use your brain this is about to CRASH they have had terrible results & a new law suit case opened how will they win ? There is 200,568 new cases of claims being filed as we speak this is going to TANK GOOD LUCK HOLDING A FALLING KNIFE | letsdothis | |
23/12/2022 11:23 | >>which already started a while back>> Evidence? | zho | |
23/12/2022 11:21 | HLN Takeover only once Pfizer and GSK exit their holdings which already started a while back will take time though admittedly. | paul planet earth | |
22/12/2022 12:59 | If HLN keeps going up (perhaps a takeover etc etc) doesn't that mean GSKs investment in HLN on its balance sheet automatically becomes worth more? | netcurtains | |
22/12/2022 10:35 | 21 Dec 22: VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain SARS-CoV-2 spike protein (B.1.351 strain) vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the European Union Results show the SARS-CoV-2 spike protein (B.1.351 strain) vaccine demonstrated an immune response against all tested variants of concern. | tradermichael | |
20/12/2022 13:41 | Good haul of dividends, though (especially when you compound the return with re-purchase of shares at the lower prices)! | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions